Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

被引：0

作者：

Orly Vardeny

James C. Fang

Akshay S. Desai

Pardeep S. Jhund

Brian Claggett

Muthiah Vaduganathan

Rudolf A. de Boer

Adrian F. Hernandez

Carolyn S. P. Lam

Silvio E. Inzucchi

Felipe A. Martinez

Mikhail N. Kosiborod

David DeMets

Eileen O’Meara

Shelley Zieroth

Josep Comin-Colet

Jaroslaw Drozdz

Chern-En Chiang

Masafumi Kitakaze

Magnus Petersson

Daniel Lindholm

Anna Maria Langkilde

John J. V. McMurray

Scott D. Solomon

机构：

[1] University of Minnesota,Minneapolis VA Center for Care Delivery and Outcomes Research

[2] University of Utah Medical Center,BHF Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health

[3] Cardiovascular Division, Department of Cardiology, Thoraxcenter

[4] Brigham and Women’s Hospital,Cardiology Department

[5] Harvard Medical School,Department Cardiology

[6] University of Glasgow,General Clinical Research Center and Division of Cardiology

[7] Erasmus Medical Center,undefined

[8] Duke University Medical Center,undefined

[9] National Heart Centre Singapore and Duke–National University of Singapore,undefined

[10] Yale School of Medicine,undefined

[11] Universidad Nacional de Córdoba,undefined

[12] Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City,undefined

[13] University of Wisconsin,undefined

[14] Montreal Heart Institute and Université de Montréal,undefined

[15] St. Boniface Hospital & University of Manitoba,undefined

[16] Bellvitge University Hospital,undefined

[17] Bio-Heart Bellvitge Institute for Biomedical Research,undefined

[18] University of Barcelona,undefined

[19] Hospitalet de Llobregat,undefined

[20] Medical University Lodz,undefined

[21] Taipei Veterans General Hospital and National Yang Ming Chiao Tung University,undefined

[22] Kinshukai Hanwa Daini Senboku Hospital,undefined

[23] Late-Stage Development,undefined

[24] Cardiovascular,undefined

[25] Renal,undefined

[26] and Metabolism,undefined

[27] BioPharmaceuticals R&D,undefined

[28] AstraZeneca,undefined

来源：

Nature Medicine | 2023年 / 29卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：3269 / 3269

共 50 条

[31] Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
Ostrominski, John W.
Vaduganathan, Muthiah
Selvaraj, Senthil
Claggett, Brian L.
Miao, Zi Michael
Desai, Akshay S.
Jhund, Pardeep S.
Kosiborod, Mikhail N.
Lam, Carolyn S. P.
Inzucchi, Silvio E.
Martinez, Felipe A.
de Boer, Rudolf A.
Hernandez, Adrian F.
Shah, Sanjiv J.
Petersson, Magnus
Maria Langkilde, Anna
Mcmurray, John J. V.
Solomon, Scott D.
[J]. CIRCULATION, 2023, 148 (24) : 1945 - 1957
[32] The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health-economic analysis of the DELIVER trial
Booth, David
Davis, Jason A.
McEwan, Phil
Solomon, Scott D.
McMurray, John J. V.
De Boer, Rudolf A.
Comin-Colet, Josep
Bachus, Erasmus
Chen, Jieling
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1386 - 1395
[33] Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Peikert, A.
Bart, B. A.
Vardeny, O.
Vaduganathan, M.
Claggett, B. L.
Desai, A. S.
Jhund, P. S.
Kosiborod, M. N.
Lam, C. S. P.
Martinez, F. A.
De Boer, R. A.
Hernandez, A. F.
Shah, S. J.
Mc Murray, J. J. V.
Solomon, S. D.
[J]. EUROPEAN HEART JOURNAL, 2023, 44
[34] Dapagliflozin in patients with heart failure and reduced ejection fraction
Giorgio Colombo
Rosa Casella
Alessia Cazzaniga
Chiara Casiraghi
[J]. Internal and Emergency Medicine, 2020, 15 : 515 - 517
[35] Dapagliflozin in patients with heart failure and reduced ejection fraction
Colombo, Giorgio
Casella, Rosa
Cazzaniga, Alessia
Casiraghi, Chiara
[J]. INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (03) : 515 - 517
[36] Dapagliflozin for patients with heart failure and reduced ejection fraction
Ferry, Abigail
[J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2022, 35 (09): : 51 - 53
[37] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V.
Solomon, S. D.
Inzucchi, S. E.
Kober, L.
Kosiborod, M. N.
Martinez, F. A.
Ponikowski, P.
Sabatine, M. S.
Anand, I. S.
Belohlavek, J.
Bohm, M.
Chiang, C. -E.
Chopra, V. K.
de Boer, R. A.
Desai, A. S.
Diez, M.
Drozdz, J.
Dukat, A.
Ge, J.
Howlett, J. G.
Katova, T.
Kitakaze, M.
Ljungman, C. E. A.
Merkely, B.
Nicolau, J. C.
O'Meara, E.
Petrie, M. C.
Vinh, P. N.
Schou, M.
Tereshchenko, S.
Verma, S.
Held, C.
DeMets, D. L.
Docherty, K. F.
Jhund, P. S.
Bengtsson, O.
Sjostrand, M.
Langkilde, A. -M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 1995 - 2008
[38] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Peled, Harry
Dau, Nhu-Quyen
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10) : 972 - 972
[39] Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial (vol 9, pg 144, 2024)
Magnani, Jared W.
Allen, Norrina B.
[J]. JAMA CARDIOLOGY, 2024, 9 (07) : 674 - 674
[40] Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction
Porras, M. A. Pabon
Clagget, B. L.
Chatur, S.
Bhatt, A. S.
Vaduganathan, M.
Fang, J.
Desai, A.
Jhund, P.
Martinez, F.
De Boer, R.
Kosiborod, M.
Lam, C.
Mcmurray, J.
Solomon, S.
Vaderny, O.
[J]. EUROPEAN HEART JOURNAL, 2023, 44

← 1 2 3 4 5 →